{"id":348549,"date":"2026-03-26T08:53:07","date_gmt":"2026-03-26T08:53:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/348549\/"},"modified":"2026-03-26T08:53:07","modified_gmt":"2026-03-26T08:53:07","slug":"10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/348549\/","title":{"rendered":"$10,000 invested in this ASX healthcare share a year ago is now worth $36,500"},"content":{"rendered":"\n

ASX\u00a0healthcare share<\/a> Starpharma Holdings Ltd (ASX: SPL<\/a>) has rocketed 365% over the past 12 months.<\/p>\n

Had you put $10,000 into this ASX\u00a0small-cap<\/a>\u00a0share in March 2025, your holdings would be worth $36,500 today. <\/p>\n

Starpharma is an Australian\u00a0biotech<\/a>\u00a0that develops drug delivery systems using proprietary polymers called dendrimers.<\/p>\n

These nanoscale molecules make medicines more effective in the body.<\/p>\n

Starpharma licenses its drug delivery technology to large pharma, and also develops its own anti-infection products.<\/p>\n

This ASX healthcare share is trading at 47 cents on Thursday, up 1.1%.<\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

What’s behind the dramatic 365% share price rise? <\/p>\n

The bulk of Starpharma’s rise over the past 12 months occurred between late September and February. <\/p>\n

In September, the ASX healthcare share rose by more than 100% after the company announced two new partnerships. <\/p>\n

Starpharma announced a new deal with drug company Genentech, which it has worked with for more than three years.<\/p>\n

The companies will develop cancer treatments using Starpharma’s proprietary DEP drug delivery technology.<\/p>\n

Under the deal, Starpharma got an upfront payment of US$5.5 million. <\/p>\n

It is also eligible to receive up to US$564 million in success-based payments over time. <\/p>\n

Starpharma granted Genentech an exclusive global licence to commercialise any products developed via the collaboration.<\/p>\n

Starpharma CEO Cheryl Maley\u00a0said:<\/p>\n

A key strategic priority for Starpharma is to build new, high-impact partnerships that unlock the full potential of our DEP platform. <\/p>\n

By actively pursuing licensing opportunities and collaborating with leading organisations, we aim to expand market reach and enable our partners to deliver significantly improved therapies to patients worldwide.<\/p>\n

The ASX healthcare share surged again when the company announced its first radiopharmaceutical partnership<\/a>. <\/p>\n

Starpharma signed a research and option agreement with Radiopharm Theranostics Ltd\u00a0(ASX: RAD<\/a>) that made it eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based payments and royalties on net sales.<\/p>\n

Maley called the deal a key milestone, and said radiopharmaceuticals was a strong area of focus for Starpharma. <\/p>\n

In its 1H FY26 report<\/a> in February, Starpharma reported a 474% increase in revenue to $10.8 million for the six months to 31 December. <\/p>\n

The half-year profit was $1,367,000, up from a loss of $5,392,000 in 1H FY24. <\/p>\n

Is it too late to buy this rising ASX healthcare share? <\/p>\n

ASX biotech shares<\/a> are notoriously risky and unsuitable for investors with a low risk tolerance. <\/p>\n

PAC Partners gives this one a buy rating with a “high risk” 12-month price target of 80 cents to $1.<\/p>\n

PAC Partners forecasts growth in partnerships as well as over-the-counter revenue over the next four years. <\/p>\n","protected":false},"excerpt":{"rendered":"ASX\u00a0healthcare share Starpharma Holdings Ltd (ASX: SPL) has rocketed 365% over the past 12 months. Had you put…\n","protected":false},"author":2,"featured_media":348550,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[134,527,111,139,69],"class_list":["post-348549","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/348549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=348549"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/348549\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/348550"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=348549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=348549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=348549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}